Trial Profile
To evaluate safety and efficacy of ziv-aflibercept (Zaltrap) in the treatment of refractory diabetic macular edema (DME).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Sep 2017
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions; Therapeutic Use
- 20 Sep 2017 New trial record